EMMAC Life Sciences Revenue and Competitors
Estimated Revenue & Valuation
- EMMAC Life Sciences's estimated annual revenue is currently $10.2M per year.
- EMMAC Life Sciences's estimated revenue per employee is $155,000
Employee Data
- EMMAC Life Sciences has 66 Employees.
EMMAC Life Sciences's People
Name | Title | Email/Phone |
---|
EMMAC Life Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 101 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5356 | 8% | N/A | N/A |
What Is EMMAC Life Sciences?
EMMAC was incorporated to capitalise on the existing medical cannabis industry in Europe, as well as the enormous market opportunities presented by the Continent's increasing pace of, and pressure for, deregulation.
keywords:N/AN/A
Total Funding
66
Number of Employees
$10.2M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
EMMAC Life Sciences News
2022-04-19 - 3 Reasons to Buy Curaleaf Stock on the Dip
Last year, it completed the acquisition of EMMAC Life Sciences Group, also completing its successful rebranding to Curaleaf International.
2022-04-17 - How CBD biomanufacturing could make Europe change and ...
Scientific publications about CBD since 1980. ... GW Pharma (acquired by Jazz Pharmaceuticals), EMMAC Life Sciences (acquired by Curaleaf)...
2022-04-06 - Curaleaf International: New Poll Shows European market is Ready for Legal
Recreational Cannabis
Curaleaf International (formerly EMMAC Life Sciences Group) is Europe's largest vertically integrated cannabis company, bringing together...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.1M | 66 | 0% | N/A |
#2 | $7.1M | 66 | 40% | N/A |
#3 | $13.5M | 66 | -3% | N/A |
#4 | $8.6M | 66 | 29% | N/A |
#5 | $8.6M | 66 | -16% | N/A |